Trial Profile
Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 in Patients With Advanced Prostate Cancer and Unfavorable Circulating Tumor Cell Counts
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Apr 2023
Price :
$35
*
At a glance
- Drugs ATL 101 Telix Pharmaceuticals (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 05 Apr 2023 Status changed from active, no longer recruiting to completed.
- 20 Apr 2022 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.
- 08 Mar 2021 Status changed from recruiting to active, no longer recruiting.